Zogenix Stock

Zogenix ROE

Delisted

The Return on Equity (ROE) of Zogenix (ZGNX) as of Aug 6, 2026 is -127.07 %. In the previous year, Return on Equity (ROE) was -56.64 % — a change of 124.34% (lower).

ROE

-127.07 %

YoY

124.34%

Last updated:

In 2026, Zogenix's return on equity (ROE) was -127.07 %, a 124.34% increase from the -56.64 % ROE in the previous year.

Access this data via the Eulerpool API

Zogenix Stock analysis

What does Zogenix do? Zogenix Inc. is an American biotech company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. The company was founded in 2006 and is headquartered in Emeryville, California. In 2009, Zogenix Inc. brought its first product to market, the prescription painkiller Zohydro. Shortly after, in 2012, the company announced the approval of Sumavel DosePro, an innovative injection technology for the treatment of migraines. In 2018, the company completed a merger with California-based Modis Therapeutics. Together, they are developing drugs for rare genetic metabolic disorders. Zogenix has a promising business model, focusing on research and development and the marketing of true innovations in the CNS and pain field. The company aims to revolutionize the medical market with its medications, rather than simply replacing existing drugs. For this reason, Zogenix collaborates closely with leading institutes and research facilities to identify and develop new active ingredients. Zogenix is divided into various business segments, each specializing in the development of new drugs and therapies. One of Zogenix's main products is the Sumavel DosePro injection technology, which allows for quick and effective treatment of migraine attacks. Another important business area for Zogenix is the development of medications and therapies for the treatment of neuropsychiatric disorders. This includes ZX008 (Fenfluramine), an investigational drug for the treatment of Dravet syndrome, a rare form of epilepsy. The medication has already been approved in Europe and is currently being reviewed in the United States. Zogenix also focuses on the development of therapies for opioid and opiate-related disorders, as well as pain management. This includes the product Zohydro, which is a long-acting opioid painkiller. Zogenix offers a variety of prescription drugs and therapies targeting various neurological disorders and pain syndromes. The company's products aim to alleviate symptoms and address the underlying causes of the diseases. In summary, Zogenix is a biotech company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. With a wide range of products and a promising business model, the company is focused on innovation in the medical industry. Zogenix Inc represents an important area of research and development for new medications in the future. Zogenix is one of the most popular companies on Eulerpool.

ROE Details

Decoding Zogenix's Return on Equity (ROE)

Zogenix's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Zogenix's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Zogenix's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Zogenix’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Zogenix stock

Return on Equity (ROE) of Zogenix is -127.07 % in 2026.

Return on Equity (ROE) of Zogenix changed from -56.64 % to -127.07 %, representing a 124.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Zogenix since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Zogenix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Zogenix

All Key Metrics — Zogenix